Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients

Patelli, Giorgio; Pani, Arianna; Amatu, Alessio; Scaglione, Francesco

doi:10.1016/j.ejca.2022.02.032

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the neutralizing response was significantly reduced in the uninfected patients on anticancer therapy compared to those uninfected in the non‐cancer control group. These results suggest that a vaccination boost should be recommended in patients receiving anticancer treatment irrespective of the type of therapy, but especially in those without previous SARS‐CoV‐2 infection [ 30 , 31 ]. Moreover, the emergence of new virus variants of concerns, such as Omicron, reinforces the need for periodical boosts, especially in patients belonging to risk groups such as cancer patients [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors

et al. 2022

View full text Add to dashboard Cite

Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post‐vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA‐1237 vaccine, and were compared with a group of 26 non‐cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS‐CoV‐2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non‐cancer groups were significant in individuals without previous SARS‐CoV‐2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non‐cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS‐CoV‐2 vaccination programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Indeed, in a prospective, single-center cohort study up to 6% of patients with solid tumors undergoing cancer treatment, mainly with poorer performance status, fail to obtain seroconversion after primary SARS-CoV-2 mRNA vaccination as compared with 0.2% of controls without cancer, accounting for a 30-fold higher probability 32 . After the third dose an additional, although incomplete, efficacy of vaccination in this population was reported, with an estimate of 35.7% of seroconversion probability 33 . On the other hand the presence of neutralizing antibodies does not necessarily proves a mechanistic role in mediating protection, due to the possible action of other immune responses leading an apparent association.…”

Section: Discussionmentioning

confidence: 92%